

10/532787



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.


The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den
The Hague,
La Haye, le

31 MAR 2005

Der Präsident des Europäischen Patentamts
Im Auftrag
For the President of the European Patent Office
Le Président de l'Office européen des brevets
p. o.



C. v.d. Aa-Jansen

Patentanmeldung Nr.
Patent application no.
Demande de brevet n°

PCT/EP 02/14859

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°:

PCT/EP 02/14859

Anmelder:
Applicant(s):
Demandeur(s):

1. Sense Proteomic Limited - Cambridge, United Kingdom
2. KOOPMAN, Jens-Oliver - Cambridge, United Kingdom (US only)
3. BLACKBURN, Jonathan M - Cambridge, United Kingdom (US only)

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Probe for mass spectrometry

Anmeldetag:
Date of filing:
Date de dépôt:

20 December 2002 (20.12.2002)

In Anspruch genommene Priorität(en)
Priority(ies) claimed
Priorité(s) revendiquée(s)

Staat:
State:
Pays:

United Kingdom

Tag:
Date:
Date:

21 December 2001
(21.12.2001)

Aktenzeichen:
File no.
Numéro de dépôt:

0130747.9

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:
Remarks:
Remarques:

Further Priority claims:

United Kingdom

15 July 2002
(15.07.2002)

0216387.1

United Kingdom

25 October 2002
(25.10.2002)

0224572.2

Sheet No. ...3...

Box No. V DESIGNATION OF STATES

Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT (if other kind of protection or treatment desired, specify on dotted line)
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | | |
|---|--|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> OM Oman |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> PH Philippines |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> JP Japan | |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> KR Republic of Korea | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> LR Liberia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> CO Colombia | <input checked="" type="checkbox"/> LS Lesotho | <input checked="" type="checkbox"/> TN Tunisia |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> LT Lithuania | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> LU Luxembourg | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> LV Latvia | |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> MA Morocco | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> MD Republic of Moldova | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> MG Madagascar | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> EC Ecuador | <input checked="" type="checkbox"/> MN Mongolia | |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> MW Malawi | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> MX Mexico | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> MZ Mozambique | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> NO Norway | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> GD Grenada | | <input checked="" type="checkbox"/> ZM Zambia |
| <input checked="" type="checkbox"/> GE Georgia | | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> GH Ghana | | |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

- ☒ VC Saint Vincent
- ☐
- ☐

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Sheet No. . . . 4

Box No. VI PRIORITY CLAIM				
The priority of the following earlier application(s) is hereby claimed:				
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application:* regional Office	international application: receiving Office
item (1) 21 Dec 2001 21.12.01	0130747.9		GB	
item (2) 15 Jul 2002 15.07.02	0216387.1		GB	
item (3) 25 Oct 2002 25.10.02	0224572.2		GB	
item (4)				
item (5)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☐ all items
 ☐ item (1)
 ☐ item (2)
 ☐ item (3)
 ☐ item (4)
 ☐ item (5)
 ☐ other, see Supplemental Box

* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)):

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA / EP

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)	Number	Country (or regional Office)
-----------------------	--------	------------------------------

Box No. VIII DECLARATIONS

<p>The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):</p>	<p>Number of declarations</p>
<input type="checkbox"/> Box No. VIII (i) Declaration as to the identity of the inventor	:
<input type="checkbox"/> Box No. VIII (ii) Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	:
<input type="checkbox"/> Box No. VIII (iii) Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	:
<input type="checkbox"/> Box No. VIII (iv) Declaration of inventorship (only for the purposes of the designation of the United States of America)	:
<input type="checkbox"/> Box No. VIII (v) Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	:

Sheet No. 5

Box No. IX CHECK LIST; LANGUAGE OF FILING																																																						
<p>This international application contains:</p> <p>(a) the following number of sheets in paper form:</p> <p style="margin-left: 20px;">request (including declaration sheets) : 5</p> <p style="margin-left: 20px;">description (excluding sequence listing part) : 26</p> <p style="margin-left: 20px;">claims : 10</p> <p style="margin-left: 20px;">abstract : </p> <p style="margin-left: 20px;">drawings : 15</p> <p style="margin-left: 20px;">Sub-total number of sheets : 56</p> <p style="margin-left: 20px;">sequence listing part of description (actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (b) below) : </p> <p style="margin-left: 20px;">Total number of sheets : 56</p> <p>(b) sequence listing part of description filed in computer readable form</p> <p style="margin-left: 20px;">(i) <input type="checkbox"/> only (under Section 801(a)(i))</p> <p style="margin-left: 20px;">(ii) <input type="checkbox"/> in addition to being filed in paper form (under Section 801(a)(ii))</p> <p style="margin-left: 20px;">Type and number of carriers (diskette, CD-ROM, CD-R or other) on which the sequence listing part is contained (additional copies to be indicated under item 9(ii), in right column):</p>	<p>This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):</p> <table style="width:100%; border-collapse: collapse;"> <tr> <td style="width: 5%;">1. <input checked="" type="checkbox"/></td> <td style="width: 85%;">fee calculation sheet</td> <td style="width: 10%; text-align: right;">:</td> <td style="width: 10%; text-align: right;">1</td> </tr> <tr> <td>2. <input type="checkbox"/></td> <td>original separate power of attorney</td> <td>:</td> <td></td> </tr> <tr> <td>3. <input type="checkbox"/></td> <td>original general power of attorney</td> <td>:</td> <td></td> </tr> <tr> <td>4. <input type="checkbox"/></td> <td>copy of general power of attorney; reference number, if any:</td> <td>:</td> <td></td> </tr> <tr> <td>5. <input type="checkbox"/></td> <td>statement explaining lack of signature</td> <td>:</td> <td></td> </tr> <tr> <td>6. <input type="checkbox"/></td> <td>priority document(s) identified in Box No. VI as item(s):</td> <td>:</td> <td></td> </tr> <tr> <td>7. <input type="checkbox"/></td> <td>translation of international application into (language):</td> <td>:</td> <td></td> </tr> <tr> <td>8. <input type="checkbox"/></td> <td>separate indications concerning deposited microorganism or other biological material</td> <td>:</td> <td></td> </tr> <tr> <td>9. <input type="checkbox"/></td> <td>sequence listing in computer readable form (indicate also type and number of carriers (diskette, CD-ROM, CD-R or other))</td> <td>:</td> <td></td> </tr> <tr> <td colspan="4" style="padding-left: 20px;">(i) <input type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)</td> </tr> <tr> <td colspan="4" style="padding-left: 20px;">(ii) <input type="checkbox"/> (only where check-box (b)(i) or (b)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter</td> </tr> <tr> <td colspan="4" style="padding-left: 20px;">(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column</td> </tr> <tr> <td>10. <input checked="" type="checkbox"/></td> <td>other (specify): covering letter</td> <td>:</td> <td></td> </tr> </table>	1. <input checked="" type="checkbox"/>	fee calculation sheet	:	1	2. <input type="checkbox"/>	original separate power of attorney	:		3. <input type="checkbox"/>	original general power of attorney	:		4. <input type="checkbox"/>	copy of general power of attorney; reference number, if any:	:		5. <input type="checkbox"/>	statement explaining lack of signature	:		6. <input type="checkbox"/>	priority document(s) identified in Box No. VI as item(s):	:		7. <input type="checkbox"/>	translation of international application into (language):	:		8. <input type="checkbox"/>	separate indications concerning deposited microorganism or other biological material	:		9. <input type="checkbox"/>	sequence listing in computer readable form (indicate also type and number of carriers (diskette, CD-ROM, CD-R or other))	:		(i) <input type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)				(ii) <input type="checkbox"/> (only where check-box (b)(i) or (b)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter				(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column				10. <input checked="" type="checkbox"/>	other (specify): covering letter	:		<p>Number of items</p>
1. <input checked="" type="checkbox"/>	fee calculation sheet	:	1																																																			
2. <input type="checkbox"/>	original separate power of attorney	:																																																				
3. <input type="checkbox"/>	original general power of attorney	:																																																				
4. <input type="checkbox"/>	copy of general power of attorney; reference number, if any:	:																																																				
5. <input type="checkbox"/>	statement explaining lack of signature	:																																																				
6. <input type="checkbox"/>	priority document(s) identified in Box No. VI as item(s):	:																																																				
7. <input type="checkbox"/>	translation of international application into (language):	:																																																				
8. <input type="checkbox"/>	separate indications concerning deposited microorganism or other biological material	:																																																				
9. <input type="checkbox"/>	sequence listing in computer readable form (indicate also type and number of carriers (diskette, CD-ROM, CD-R or other))	:																																																				
(i) <input type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)																																																						
(ii) <input type="checkbox"/> (only where check-box (b)(i) or (b)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter																																																						
(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column																																																						
10. <input checked="" type="checkbox"/>	other (specify): covering letter	:																																																				
<p>Figure of the drawings which should accompany the abstract:</p>	<p>Language of filing of the international application: English</p>																																																					
<p>Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE</p> <p><i>Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).</i></p> <div style="height: 100px; border: 1px solid black; margin-top: 10px; position: relative;"> <div style="position: absolute; top: 10px; left: 10px; font-family: cursive; font-size: 1.2em;">Stratagem IPM Ltd.</div> <div style="position: absolute; bottom: 10px; left: 10px;"> <p>Stratagem IPM Ltd</p> <p>Representative & Authorised Agent for the Applicants</p> </div> </div>																																																						

For receiving Office use only			
1. Date of actual receipt of the purported international application:	20.12.2002	20 DEC 2002	<p>2. Drawings:</p> <p><input type="checkbox"/> received:</p> <p><input type="checkbox"/> not received:</p>
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:			
4. Date of timely receipt of the required corrections under PCT Article 11(2):			
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid		

For International Bureau use only
<p>Date of receipt of the record copy by the International Bureau:</p>

This sheet is not part of and does not count as a sheet of the international application.

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International Application No. **PCT/EP 02 / 1 4 8 5 9**

20 12. 2002

Applicant's or agent's
file reference

P1643

Date stamp of the receiving Office

Applicant

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE **100 EUR [T]**

2. SEARCH FEE **945 EUR [S]**

International search to be carried out by _____
(If two or more International Searching Authorities are competent to carry out the international search, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

Basic Fee

Where item (b) of Box No. IX applies, enter Sub-total number of sheets } **X**
Where item (b) of Box No. IX does not apply, enter Total number of sheets }

[b1] first 30 sheets **444 EUR [b1]**

[b2] 26 x 10 = **260 EUR [b2]**
number of sheets fee per sheet
in excess of 30

[b3] additional component (only if sequence listing part of description
is filed in computer readable form under Section 801(a)(i), or
both in that form and on paper, under Section 801(a)(ii):

400 x _____ = **[b3]**
fee per sheet

Add amounts entered at b1, b2 and b3 and enter total at B **704 EUR [B]**

Designation Fees

The international application contains 5 + designations.

5 x 96 EUR = **480 EUR [D]**
number of designation fees amount of designation fee
payable (maximum 5)

Add amounts entered at B and D and enter total at I **1184 EUR [I]**

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT (if applicable) **[P]**

5. TOTAL FEES PAYABLE **2229 EUR**
Add amounts entered at T, S, I and P, and enter total in the TOTAL box **TOTAL**

☐ The designation fees are not paid at this time.

MODE OF PAYMENT

☒ authorization to charge deposit account (see below) ☐ postal money order ☐ cash ☐ coupons
☐ cheque ☐ bank draft ☐ revenue stamps ☐ other (specify):

AUTHORIZATION TO CHARGE (OR CREDIT) DEPOSIT ACCOUNT

(This mode of payment may not be available at all receiving Offices)

☒ Authorization to charge the total fees indicated above.
☒ (This check-box may be marked only if the conditions for deposit accounts of the receiving Office so permit) Authorization to charge any deficiency or credit any overpayment in the total fees indicated above.
☐ Authorization to charge the fee for priority document.

Receiving Office: RO/ **EP**

Deposit Account No.: **28050326-FB Ltd**

Date: **20 Dec 2002**

Name: **S J GENTLE**

Signature: 

fb FORMALITIES BUREAU

To:	Receiving Section	From:	Sue Gentle
Company:	European Patent Office	Company:	Formalities Bureau Limited
Fax No.	7700 31 70 340 4600	Fax No.	+44 (0)870 161 1054
Date:	20 December 2002 10:51:36	No. of Pages:	(including this one)
Re:			

Message:

New PCT Application
"PROBE FOR MASS SPECTROMETRY"
Applicant: Sense Proteomic Limited
Our Ref: P1643

PCT/EP 02 / 1 4 8 5 9

EPA EPO-OEB DG 1 Requ:	
20. 12. 2002	
11	ANL. ZEICHN.

Please confirm receipt of this facsimile by return.

The information in this facsimile is confidential and may be legally privileged. It is intended for the exclusive attention of the addressee stated above and should not be copied or disclosed to any other. If you have received this transmission in error please contact the sender.

fb FORMALITIES BUREAU

Formalities Bureau Ltd
4 The Gate House,
2 High Street
Harpenden
Hertfordshire
AL5 2TH
mail@fbureau.co.uk
UK Tel 0870 161 1053
UK Fax 0870 161 1054
INT Tel +44 1582 466718
INT Fax +44 1582466708

VIA FACSIMILE CONFIRMATION VIA COURIER

European Patent Office
PB 5818
Patentlaan 2
NL 2280 HV
Rijswijk
HOLLAND

20 December 2002

Dear Sirs

New PCT Application
"PROBE FOR MASS SPECTROMETRY"
Applicant: Sense Proteomic Limited
Our Ref: P1643

We are enclosing the following documents with this letter:

Form RO/101	1 copy
Specification	3 copies
Claims, Abstract, Drawings	3 copies
Fee Calculation Sheet	1 copy
EPO Form 1037	2 copies

The authorisation for Stratagem IPM Ltd to represent Sense Proteomic Limited will follow shortly.

It is requested that this application be accorded a filing date no later than 21 December 2002.

Calculation of fees and authorisation to charge to Deposit Account No 28050326 in the name of Formalities Bureau Ltd.

The Patent Office is requested to telephone 44-870 161 1053 if anything is not in order.

Yours faithfully



Sue Gentle



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Einsender / Sender / Expéditeur :

Formalities Bureau Ltd
The Gatehouse
2 High Street
HARPENDEN
Herts
AL5 2TH
GB

✉ D-80298 München
☎ (+49-89) 2399-0
Tx 523 656 epmu d
Fax (+49-89) 23 99-44 65
✉ P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
☎ (+31-70) 340-2040
Tx 31 651 epo nl
Fax (+31-70) 340-3016
✉ D-10958 Berlin
☎ (+49-30) 25901-0
Fax (+49-30) 25901-840

**Bestätigung über den
Eingang nachgezeichneter
Unterlagen für Patentan-
meldungen/Patente beim
Europäischen Patentamt**

**Acknowledgement of
receipt for subsequently
filed items relating to
patent applications/patents
at the European Patent
Office**

**Accusé de réception à
l'Office européen des bre-
vets de pièces produites
postérieurement au dépôt
d'une demande de brevet/
à la délivrance d'un brevet
européen**

Datum und Ort des Eingangs sind aus
der Perforation dieser Eingangsbestäti-
gung ersichtlich
(M + Datum = Einreichungsort München;
H + Datum = Einreichungsort Den Haag;
Datum + B = Einreichungsort Berlin)

Date and place of receipt are shown by
the perforation appearing on this receipt
(M + date = Munich as place of receipt;
H + date = The Hague as place of receipt;
date + B = Berlin as place of receipt)

La date et le lieu de réception sont indi-
qués par la perforation du présent accusé
de réception
(M + date = pièces reçues à Munich;
H + date = pièces reçues à La Haye;
date + B = pièces reçues à Berlin)

Eingereichte Unterlagen

Items filed

Pièces envoyées

Anmeldungs- (und Direktions-*) Nr./Patent Nr. Application (and Directorate*) No./Patent No. N° de la demande (et de la direction*)/n° du brevet	Ihr Zeichen Your reference Votre référence	ggfs. Art und Datum der Unterlagen** Nature and date of items (optional)** Nature et date des pièces (facultatif)**
1	02PA00049	PCT Request - 20 Dec 2002
2		spec,claims,abstract,draw
3		Letter 20 Dec 2002
4		
5		
6		
7		
8		
9		
10		

* falls bereits bekannt

* if already known

* si déjà connu

** Der Eingang der angegebenen Unterlagen
wird bestätigt.
Enthält diese Spalte keine Eintragungen, so
wird lediglich bestätigt, daß eine Sendung
zu dem angegebenen Aktenzeichen einge-
gangen ist.

** The receipt of the items indicated is
confirmed.
If this column does not contain any entries,
it is only confirmed that an item has been
received for the indicated file.

** La réception des pièces indiquées est
confirmée.
Faute de mention dans cette colonne, le
présent accusé de réception se rapporte à
une pièce quelconque envoyée sous la
référence indiquée.

Probe for mass spectrometry

The present invention relates to a probe for the analysis of one or more analytes, particularly proteins or compounds capable of binding or otherwise interacting therewith, by laser desorption/ ionisation mass spectrometry, more particularly MALDI MS; It also relates to a protein microarray, a method of producing a protein microarray and a method of analysing a protein microarray.

Such a mass spectrometry probe, upon which a microarray has been fabricated, enables interrogation of protein - small molecule interactions in a label-free manner by desorption and ionisation of analytes (e.g. protein, drug or drug candidate, carbohydrate, DNA, RNA or other test molecule). The probe and methods are particularly useful in the drug discovery process, for example in hit series evaluation, lead optimisation, predictive toxicogenomics and metabolite profiling.

Analysis of disease processes and drug effects have traditionally focussed on genomics, whereas proteomics, the study of the expressed fraction of a genome, offers a more direct analysis of proteins and their inter-action. Proteomics was initially the quantitative and qualitative study of whole cell, tissue, organ or organism protein expression or fractions thereof. Often it involves comparing samples of similar biological origin exposed to different conditions or comparing diseased and non-diseased tissue. One advantage of proteomics over genomics is that it allows quantitative identification and analysis of proteins; by contrast, genomics can only predict the presence of proteins on the basis of mRNAs that might be translated into proteins. Furthermore, proteomics can identify posttranslational modification of proteins and can therefore draw conclusions about the activity of proteins rather than merely describing its presence.

Conventional analytical methods in proteomics are based on 2D-gel electrophoresis for protein separation followed by proteolytic digestion of the proteins and analysis by mass spectrometry. Alternatively Edman degradation can be used for protein identification after separation. However, both methods suffer limitations due to their bias towards highly expressed proteins and the destructive method of separation. Therefore proteomic methods which avoid the need for 2D-gel electrophoresis, such

as isotope coded affinity tag (ICAT, Gygi et al. 1999), tandem affinity protein purification (TAP, Gavin et al. 2002) and protein microarrays (McBeath and Schreiber, 2000), are gaining popularity. Furthermore, these new methods have broadened the scope of proteomics from collecting and cataloguing data to a stage where relations between molecules can be assigned; this is now referred to as functional proteomics.

Protein microarrays have most commonly taken the form of collections of immobilised antibodies that can be used, for example, to monitor protein expression levels in a miniaturised ELISA format (Schweitzer et al. 2002). The use of protein microarrays to analyse the function, rather than simply the abundance, of the immobilised proteins have received limited attention but recent examples include the analysis of substrate specificity within a set of yeast kinases (Zhu et al. 2000) and the identification of calmodulin- and phospholipid-binding proteins within a proteome-scale collection of yeast proteins (Zhu et al. 2001).

To date, protein microarrays have been analysed by enhanced chemo-luminescence (ECL), fluorescent or radioactive labels or via antibody based detection systems, but not by mass spectrometry. The current methods of analysing protein microarrays are therefore restricted by the availability of appropriate labelled ligands. Examples of labelled ligands that have been used successfully include fluorescently-labelled antibodies and radio- or fluorescently-labelled small molecule ligands. However, for drug-like small molecules, which often have molecular weights of less than 1000 Da, neither radio- or fluorescent labels are desirable; radiolabels are disfavoured for health and safety reasons, whilst the introduction of a fluorophore into the small molecule could significantly perturb the structure activity profile in an unpredictable manner. It is therefore clear that a label-free method to detect interactions in a microarray format would be a major advance and would greatly broaden the range of applications to areas where labelled compounds are not available or where labelling would alter the properties of the ligand. This would be particularly useful in the early stage of drug discovery, where great numbers of compounds are screened against proteins.

Amongst the label-free detection methods that are currently available, mass spectrometry has the unique advantage of being able to determine not only the

presence but also the identity of a given ligand. However, the development of a MALDI MS-compatible protein microarray is complex since existing methods for forming protein microarrays do not transfer readily onto to a MALDI target. There are a number of reasons why this is the case, inter alia the specialised nature of the probe surfaces and the potential for salts present in reaction buffers to interfere with the detection method. In addition, procedures known in the art for MALDI typically require the co-crystallisation of the aqueous analyte with acidic energy absorbing molecules, or 'matrix', to promote ionisation of the analytes (Karas and Hillenkamp, 1988). The method of co-crystallising analyte and matrix for MALDI, as known in the art, typically results in a heterogeneous crystallisation process and yields discrete, spatially separated crystals that each contain differing amounts of matrix and analyte. As a consequence it is often observed that individual crystals contain insufficient analyte for analysis by MALDI. This in turn results in a requirement for the analyser to sample multiple (ie. 10-100 or more) discrete locations within a given target area in order to obtain a good analyte signal; this is sometime referred to as "the search for the sweet spot" and imposes a significant lower limit on the size of individual target areas that can be routinely interrogated by MALDI MS methods known in the art. Infact, the target area generally has as area of at least 0.5mm^2 .

In order to generate MALDI MS-compatible protein microarrays, solutions for the aforementioned shortcomings of the prior art are required that enable both miniaturisation of the target areas and functional analysis of the arrayed proteins.

Some examples of the affinity capture of analytes for mass spectrometric analysis have been described to date. However these examples relate to the use of single antibodies, nitroloacetic acid, anion exchangers or cation exchangers immobilised on the surface of the MALDI target or the use of bead based affinity capture reagents (Hutchens and Yip, 1993, Brockman and Orlando 1995, Wang et al 2001). However, all these methods suffer from one or more of the following limitations:

- a) Partial or total loss of biological activity because of amine-based coupling of the analyte or the bait onto the probe;
- b) Low specificity between the analyte and the surface which can lead to the non-specific binding of several analytes to the surface (e.g. ion-exchange surfaces);

- c) Low affinity of the analyte to the surface which can lead to leaching of the analyte from the surface during any wash procedures (e.g. ion-exchange and nitriloacetic acid surfaces);
- d) The affinity capture surface lacks non specific protein resistance, which can lead to high levels of non-specific protein binding which would interfere with the analysis of a protein microarray;
- e) The availability of only a limited number of affinity capture proteins.

Thus existing methods do not enable the immobilisation of large numbers of different, purified proteins in the form of a MALDI MS-compatible microarray suitable for functional analysis of the microarrayed proteins.

Summary of the Invention

The primary object of this invention is the development of a probe for the production of a protein microarray (as opposed to an array) which can be interrogated by means of laser desorption/ ionisation mass spectrometry, particularly matrix assisted laser desorption/ ionisation (MALDI).

The invention also relates to methods leading to the production of such a probe, a protein microarray which can be interrogated by means of laser desorption/ ionisation mass spectrometry, particularly matrix assisted laser desorption/ionisation (MALDI) and methods of analysing such a probe or protein microarray.

Some of the significant advances leading to the development of such a probe are described in Applicant's co pending application WO 01/57198 and are thus not dealt with in depth herein.

In order to generate MALDI MS-compatible protein microarrays, solutions for the aforementioned shortcomings of the prior art are required that enable both miniaturisation of the target areas and functional analysis of the arrayed proteins.

As defined herein a probe is a support which is capable of acting as a target in analysis by laser desorption/ionisation mass spectrometry, for example matrix assisted laser desorption/ionisation (MALDI). The probe carries the analytes, for example proteins, during such processes and interacts with the repeller lens of the ion-optic assembly found in laser desorption/ionisation time-of-flight (TOF) mass spectrometers of the art, such that the analytes are converted to gaseous ions to permit analysis. For example, the probes of the invention may be derived from targets for MALDI analysis as known in the art, which are treated such that a high affinity protein binding moiety e.g. streptavidin, avidin or neutravidin molecules are present on the probe surface which bind biotinylated proteins for subsequent analysis. For example, conventional glass or gold MALDI targets may be used.

As defined herein a micro array is an array where the size of the discrete target areas i.e. the individual areas probed by a laser, is in the order of micrometers or less. Whilst at the upper end of the scale, around 1000 micrometers diameter, they may be visible to the naked eye, at the lower end of the scale the discrete target areas will not be clearly distinguished by the naked eye.

The arrays will typically be arranged in matrices comprising several rows and columns. The number of discrete target areas will depend upon what is being screened though it is generally desirable to have a high density of these discrete areas on the probe surface as this will facilitate high through put screening. Typically a probe will comprise at least 10, more preferably at least 100, more preferably at least 1000 and as many as 10,000 or more target areas produced thereon. (Typically a probe surface will have an area of around $10,000\text{mm}^2$ – a Bruker probe has an area of 10292mm^2 although there is no requirement to use the whole of the probe and the microarray can be applied in one or more matrices thereon.) The actual density in a given matrices will depend upon the size of the discrete target area (which will typically be printed as a spot) and the spacing between adjacent spots. Thus the discrete target areas will typically be present at a density of greater than 1 discrete target areas per mm^2 within any matrices.

An analyte capture moiety is the moiety which captures the component which is being screened. Preferably, though not essentially the capturing element is a protein

although it is possible to have an array in which, for example, small molecules are bound to the surface and thus to screen for proteins.

The term proteins, as used herein, is used to include both whole proteins and sub units or domains thereof.

Fusion protein, as used herein, is used to refer to a protein, which has a tag, for example, a biotinylation consensus sequence or phleomycin/zeocin resistance binding protein attached thereto.

Linker molecules are molecules which function as their name suggests. They are molecules comprising functional groups which allow bridges to be formed between different molecules.

According to a first aspect of the invention there is provided a probe, for use with a laser desorption/ ionisation mass spectrometer, comprising a support having an electroconductive target surface thereon characterized in that the target surface comprises a micro array having a plurality of discrete target areas presenting one or more analyte capture moieties.

The development of such a probe will enable high through put screens to be conducted and a plurality of protein interactions to be studied.

Another significant development enabling the "miniaturisation" of a protein array formed on a MALDI target derives from the application of the Applicant's COVET technology described in WO 01/57198. Briefly, using this technology they are able to create from cDNA libraries expressed proteins, which carry a "sequence tag" that can be used to capture the proteins with a high affinity and in a specific orientation on the microarray surface. This firstly enables proteins e.g. a protein library to be stably immobilized such that leaching of protein from the surface is avoided and secondly the oriented immobilisation of the fusion protein onto the surface ensure maximum biological activity.

Yet another significant aspect of the invention, when compared to current protein microarrays, is the provision of such a probe with an electro conductive surface. This surface which includes semi conductive surfaces is essential where the probe is to be subjected to MALDI MS analysis. Whilst the support could be made wholly of an electro conductive material (which term is used herein to include semi conductive materials) it is preferred to coat a rigid support, e.g. a glass, with an electro conductive material such as, for example, gold although any suitable metal, for example, silver, platinum, iridium, wolfram, copper, cobalt, nickel, and iron or mixtures thereof, or a semiconductor e.g. silicon , graphite or germanium could be used.

Where the probe or protein microarray is produced on e.g. a standard size microscope glass slide it can be mounted in an adapter, which carries it into a mass spectrometer. Such an adaptor is described in Applicant's co pending UK application number 216387.1.

A further significant development, and one which may be viewed independently of the specific applications described herein, has been in the way the Applicant has overcome the problems caused by non specific protein binding. The Applicant has overcome this particular problem by providing a layer resistant to non specific protein binding onto the probe surface. More particularly, the microarray surface is modified by the inclusion of a layer of molecules which repel proteins. These protein repellant molecules which include, for example, polyethyleneglycol may be bound to the probe surface via a linker, such as, for example, a poly amino acid which readily binds to e.g. a glass or gold surface and whose amino or carboxyl side groups can be used to bind the protein repellant molecules such that they reach out from the probe surface. The skilled man will appreciate that other functionalized molecules could be used. Preferably the analyte binding moieties are incorporated in a position where they extend out from the surface. Preferred protein binding moieties include e.g. biotin, biotin-neutravidin, and bleomycin, and these and other moieties can be incorporated into the layer either via these functional groups on the linker molecules and/ or via functional groups on the protein repellant molecules. Typically the affinity capture moieties are incorporated in small proportions (typically less than 20%) relative to the protein repellant molecules.

In this way the Applicant has been able to introduce the protein capture moieties not only in a homogeneous, spatial defined arrangement but also in a manner which enables high affinity binding in a specific manner. The resulting surface combines selectivity for the capture of biological macromolecules on the probe with reduced non specific binding of the type commonly observed on underivatised glass or metal surfaces and additionally results in a homogeneous distribution and orientation of the captured biological macromolecules.

The component molecules responsible for repelling non specific proteins include molecules which are generally hydrophilic in nature. They include polymers, such as, for example, polyethylene glycol, dextran, polyurethane and polyacrylamide and self assembled monolayers (SAM). Preferably the polymers comprise one or more functional side groups via which the protein capturing moieties can be attached. In the case of polyethylene glycol the functional group is a hydroxyl group. The molecules responsible for repelling non specific proteins may be bound directly to the surface as in, for example the case of SAM's or they may be attached via a linker. Particularly preferred as linkers are poly amino acids such as, for example, poly L lysine, poly L aspartic acid, poly L glutamic acid or mixtures thereof. These have amino or carboxy side chains via which the molecules responsible for repelling non specific proteins can be attached and which can additionally be used to attach the protein capturing moieties. Alternatively, or in addition, the protein capturing moieties can be attached via the component molecules responsible for repelling non specific proteins. Fig 7 illustrates the binding of such molecules and contrasts the defined orientation which can be achieved by this ordered coupling compared to that achieved using current antibody binding techniques which result in random coupling.

In a preferred embodiment the probe has as it's protein capture moieties either a biotin binder e.g. neutravidin, avidin or streptavidin or a bleomycin resistant protein binder e.g. bleomycin. The proteins are bound to the probe to create a protein microarray by printing a plurality of bacterial, yeast, sf9 or mammalian cell lysates containing fusion proteins in which a high affinity tag e.g. biotin or zeocin resistant protein (ZRP) is expressed onto the capture surface. Proteins are derived from the expression of a cDNA library and each individual clone is tagged at the C-terminus and/ or on the N-

terminus with a consensus sequence, which will enable high affinity recognition of the protein even in the presence of the otherwise protein repellent molecules. Only the recombinant, tagged protein can recognise the capture surface and other proteins from the lysate can be washed away as they do not bind to the protein repellent surface and do not have a high affinity to the protein binding moieties present in the layer.

Another aspect of the invention is the study of the full protein complement, or a significant fraction thereof, of given cell or tissue type using a probe or protein microarray according to the invention.

According to a further aspect of the present invention there is provided a method of producing a protein microarray for use with laser desorption ionisation mass spectrometer comprising providing a probe of the invention and depositing protein in registration with the protein capturing moieties in the discrete target area.

According to a further aspect the invention utilizes the probes and protein microarrays to analyse and screen various reactions.

One method of analysis by laser desorption/ionisation mass spectrometry comprises the steps of:

- a) providing a probe of the invention;
- b) bringing said probe into contact with one or more proteins; and
- c) performing laser desorption/ ionisation mass spectrometry on the proteins on the surface of the probe.

In one embodiment the method comprises, between step b) and c), an additional step of removing unbound molecules from the probe by washing.

In another embodiment the one or more proteins are contained in a mixture of proteins.

In yet a further embodiment, which is a method for identifying a protein on the surface of the probe, the method comprises the additional steps of:

- d) determining the mass of the protein molecule;

- e) performing a digestion upon a replicate sample of said protein on a further probe or probe surface; and
- f) performing laser desorption/ ionisation mass spectrometry on the peptides resulting from step e) to identify said protein(s).

In another embodiment there is a method for analysing the function of a protein on the surface of the probe and a molecule interacting with said protein and which comprises the alternative and additional steps of:

- c) bringing a protein on the probe surface into contact with one or more test molecules;
- d) removing unbound test molecules from the probe surface;
- e) performing laser desorption/ ionisation mass spectrometry on the protein and any molecule that had been specifically retained on the probe surface through interaction with the protein to determine the identity of the protein and/or test molecule.

The test molecule may be a small molecule, protein, or a nucleic acid e.g. DNA or RNA.

In a further embodiment there is a method for analysing the function of a protein on the surface of the probe and a molecule interacting with said protein and which comprises the alternative and/or additional steps of:

- c) bringing a protein on the probe surface into contact with one or more test substrates; and
- d) performing laser desorption/ ionisation mass spectrometry on the protein and test substrates to determine the presence and/or identity of products of catalysis of said test substrates by the protein.

In one embodiment a cDNA library which has been cloned to express a high affinity tag is expressed and after expression of each clone, the tagged library proteins are captured by the protein affinity moieties and dried onto the microarray, overlaid with a proteolytic agent of biological or chemical origin, cleaved into fragments, overlaid with energy absorbing matrix molecules prepared in a non-aqueous solvent that is spiked with and anti evaporative agents such as glycol. The energy absorbing

molecules are applied to the protein microarray in a new formulation at volumes of e.g. a few nanoliters to form a continuous layer of microcrystals.

This use of energy absorbing molecules in this way is yet another and independent aspect of the invention.

According to a further aspect of the present invention there is provided a solution comprising energy absorbing matrix molecules, a non-aqueous solvent and an anti evaporative agent.

According to a further aspect of the present invention there is provided a method of analysing a probe of the invention in which energy absorbing molecules are deposited in a manner which denatures and thus unbinds a protein from a protein capturing moiety leaving the denatured protein lying unbound on the surface.

The energy absorbing molecules form a homogenous layer of crystals in discrete locations in registration with the protein capturing moieties and captured protein.

The homogenous layer of crystals is substantially continuous such that individual crystals are not visible at a 100 fold magnification and there are no visible gaps. It also has a substantially uniform depth, such that there is no apparent variation in crystal size at a 100 fold magnification.

The energy absorbing molecules are deposited onto the surface in a non aqueous solvent and the non aqueous solvent is evaporated off. Preferably the non aqueous solvent is an organic solvent, such as, for example, acetone or butanone. Preferably the non aqueous solvent includes a modifier which controls the rate of evaporation such that crystallisation of the energy absorbing molecules occurs on the probe. Suitable modifiers include glycerol, polyethyleneglycol and thioglycerol. Preferably the energy absorbing molecules are deposited in a mixture of from 80 - 99.9%, preferably 99% organic solvent e.g. acetone to 20 - 0.1%, preferably 1% of modifier e.g. glycerol (vol/vol). Typical energy absorbing molecules include crystals of α -cyano-4-hydroxy-cinnamic acid, sinapinic acid, gentisic acid, nifidine,

succinic acid, 1,8,9,-anthracenitriol, 3-Indoleacrylic acid, 2-(hydroxyphenylazo) benzoe-acid, 4-nitroanilin and combinations thereof.

Preferably the energy absorbing molecules are deposited in registration with the protein and each protein spot is overlaid with a similar sized spot of the energy absorbing molecules.

A further application of the protein microarray is the parallel analysis of protein-protein, protein-nucleotide and protein small molecule interaction by mass spectrometry.

Yet another aspect of the invention is its usefulness to screen small molecule compound libraries on the probe to detect binding of drug-like small molecules to proteins that are derived from a proteome, where the small molecules do not carry a label such as a radiolabel or a fluorescent label.

In order to achieve a high density of individual samples on the microarray the energy absorbing molecules need to be arranged in microcrystals on the surface. The matrix forms a homogenous layer of flat crystals without significant gaps between them and can be deposited in very small quantities on the microarray.

In contrast to the prior art in which matrix and analyte are co crystalised in an aqueous solvent, the Applicant uses two distinct steps in which first the protein is deposited in an aqueous solvent and then the energy absorbing molecules are deposited such that they crystallise out from the non aqueous solvent on the probe. This has the advantage that the protein is deposited in its biological form. However, using a non aqueous solvent to deliver the energy absorbing molecules allows the formation of a homogenous layer of microcrystals. This has two benefits. First the formation of a homogenous layer means it is not necessary to search for a sweet spot as the homogenous layer guarantees protein in the presence of energy absorbing molecules and secondly it results in more accurate measurement due to the even nature of the layer.

Another aspect of the invention is the automated analysis of small molecules binding to proteins present on the microarray. The molecular weight of small molecule ions, which are stored in a database can be compared with the measured molecular weight of a compound library and therefore the relationship between the small molecule and protein in the array can be assigned.

The various aspects of the invention will now be described, by way of example only, with reference to the following figures and examples in which:

Fig 1a show six screenshots taken from a Bruker Autoflex mass spectrometer flexcontrol tool comparing the crystal surface of one aspect of the invention with that obtained practicing the method of the prior art. The six screenshots show three different matrices prepared in two different ways.

On the left side (top to bottom) are:

- i) α -cyano-4-hydroxy-cinnamic acid;
- ii) sinapinic acid; and
- iii) gentisic acid.

All have been prepared in 99% acetone, 1% glycerol (v/v) .

On the right hand side (top to bottom) are the same matrices

- iv) α -cyano-4-hydroxy-cinnamic acid;
- v) sinapinic acid; and
- vi) gentisic acid.

prepared in aqueous solvents as per the prior art.

Fig 1b shows a photomicrograph of α -cyano-4-hydroxy-cinnamic acid crystals.

The matrix was dissolved in 99% acetone v/v, 1% glycerol and arrayed onto a gold coated glass slide with an affinity capture surface. The printing density is 562 micrometers from spot center to spot center.

Fig 2a shows a mass spectrum acquired from a protein microarray demonstrating the capture of 1500 femtogram insulin-biotin on a affinity capture surface. There are three insulin-biotin peaks visible due to different degree of biotinylation. Up to 3 biotin molecules were observed on insulin in the range of 6000 dalton. Two additional

peaks are observed at 7300 dalton and 14600 dalton and are assigned as Neutravidin $[MH]^+$ and $[MH]^{2+}$.

Fig 2b shows a mass spectrum acquired from a protein microarray demonstrating the capture of 15 femtogram insulin-biotin on a affinity capture surface. Two insulin-biotin peaks are visible in the area of 6000 dalton. Two additional peaks are observed at 7300 dalton and 14600 dalton and assigned as Neutravidin $[MH]^+$ and $[MH]^{2+}$.

Fig 3a shows the detection of Cyclosporin by mass spectrometry on a PEG-PLL-Biotin Neutravidin affinity capture surface. Cyclosporin is detected at 1205 dalton and Neutravidin $[MH]^+$ and $[MH]^{2+}$ peaks are present at 7310 and 14652 dalton.

Fig 3b shows the detection of Ketoconazole by mass spectrometry on a PEG-PLL-Biotin Neutravidin surface. Ketoconazole is detected at 534 dalton and Neutravidin $[MH]^+$ and $[MH]^{2+}$ peaks are at present at 7225 and 14501 dalton.

Fig 3c shows the detection of Quinidine by mass spectrometry on a PEG-PLL-Biotin Neutravidin surface. Quinidine is detected at 327 dalton and Neutravidin $[MH]^+$ and $[MH]^{2+}$ is present at 7310 and 14652 dalton.

Fig 4a shows the detection of ADP and ATP. ATP was enzymatically synthesized from the reaction of ADP, creatine phosphate and creatine phosphate kinase in 25 mM ammonium bicarbonate at pH 7.4. $[ADP]^-$ was detected at 427.6 dalton and $[ADP+Na]^-$ 449.6 dalton. The products of the creatine phosphate kinase reaction were detected at 507.6, 529.6, 551.6 and 573.8, which fits well with the expected molecular weight of $[ATP]^-$ and three ATP sodium adducts $[ATP Na]^-$, $[ATP Na_2]^-$ and $[ATP Na_3]^-$. Control reactions in which either one of the substrates ADP or creatine phosphate or the enzyme creatine phosphate kinase was omitted didn't show ATP peaks.

Fig 4b shows a MALDI mass spectrum detecting human cytochrome p450 oxidation products of dibenzylfluoresceine (DBF). DBF was oxidized by cytochrome P450 and a metastable oxidation product was detected at 530 dalton. Further molecular ions of oxidized dibenzylfluoresceine were detect at 477 and 461 dalton presenting two monobenzyfluoresceine derivatives.

Fig 5 shows the capture of a biotinylated 72 Kda polypeptide on a PEG-PLL-Biotin Neutravidin coated gold target. The protein was expressed in 200 microliter *Escherichia coli* culture, the bacteria were lysed with lysozyme and Dnase treated. The resulting bacterial lysate was spotted onto a affinity capture surface and incubated for 4 hours. The probe was then washed with 1 mM Tris-HCL pH 7.5 0.1% Triton followed by two washes with 1 mM Tris-HCl pH 7.5 for desalting and removal of detergent. The probe target was then dried under nitrogen and overlaid with energy absorbing matrix (α -cyano-4-hydroxy-cinnamic acid dissolved in acetone). The mass spectrum was acquired in linear mode using the delayed extraction technique at low laser power.

Fig 6 shows identification of genetically engineered *Schistosoma mansoni* Glutathione-S-Transferase BCCP fusion protein that was expressed in *Escherichia coli*. Glutathione-S-Transferase was captured from a crude bacterial lysate on the probe by the use of affinity capture polymers. The captured analyte was washed and digested on the probe overlaid with energy absorbing matrix dissolved in acetone and analysed by a MALDI TOF mass spectrometer. The resulting peptide masses were used for a protein fingerprint analysis and the fusion protein was identified as Glutathione-S-Transferase from *Schistosoma japonicum*.

Fig 7 shows random and orientated coupling of proteins on a probe for example a MALDI target, microtiter plate or a microscope glass slide.

Figure 8. The binding of poly-L-lysine poly ethylenglycol biotin polymer (PEG-PLL-biotin) to a biosensor is shown. Subsequently, neutravidin and a protein lysate from *E. coli* containing biotin tagged Glutathione-S-transferase (GST-BCCP) was added to the surface followed by a washing period for each step.

Figure 9a and 9b Mass spectra of distinct forms of the glycoprotein Fetuin on immobilised lectins. (a) Biotinylated peanut lectin was immobilised on a PEG-PLL-biotin-neutravidin surface for the capture of the glycoprotein Fetuin. The $[M+H]^+$, $[2M+H]^+$ molecular ions of the lectin were observed at 25774 and 51461 dalton and the $[M+H]^+$ molecular ion of neutravidin was observed at 14300 dalton. Peaks

accounting for the molecular ions of the glycoprotein were observed at 40136 and 42731 dalton. (b) Biotinylated wheat germ agglutinin was immobilised on PEG-PLL-biotin-neutravidin surface and used for the specific capture of the glycoprotein Fetuin. The $[M+H]^+$, $[2M+H]^+$ molecular ions of the lectin were observed at 17709 and 35584 daltons and $[M+H]^+$, $[2M+H]^+$ molecular ions of neutravidin were observed at 14300 and 28600 dalton. The $[M+H]^+$ molecular ion of the glycoprotein Fetuin was observed at 44163 dalton and two peaks at 25943 and 32158 daltons were specific for the glycoprotein and represent most likely breakdown products.

Fig 10a shows the specific binding of a Rhodamine-lactose derivative to the lectin from *Arachis hypogea*. (a) A PEG-PLL-Neutravidin *Arachis hypogea* surface was overlaid with 1 mM lactose-rhodamine conjugate and washed three times with 1 mM Tris-HCl, pH 7.5 and overlaid with a solution of energy absorbing α -cyanohydroxycinnamic acid dissolved in acetone. The following MALDI MS analysis shows a molecular ion at 830.32 dalton which fits with $[MH]^+$ of lactose-rhodamine.

Fig 10b Shows the MALDI MS analysis of the lactose-rhodamine conjugate as used in the experiment. The lactose-rhodamine molecular ion is detected as well as the sodium adduct molecular ion at 834 dalton.

Fig 10c A PEG-PLL neutravidin surface with the immobilised FK506 binding protein was overlaid with a 1 mM lactose-rhodamine conjugate and washed three times with 1 mM Tris-HCl pH 7.5 and overlaid with energy absorbing matrix molecules dissolved in acetone. The MALDI MS analysis shows no molecular ions of lactose rhodamine.

Table 1 shows the molecular weights of peptides which could be assigned to three protein by protein fingerprint analysis of a Glutathione-S-transferase digest. The molecular weights of the peptides were used to search NCBI nr database using the MASCOT search engine with a mass accuracy of 50 ppm. The matched proteins are glutathione-S-transferase, avidin and trypsin.

Detailed description

1. Preparation of a probe according to one aspect of the invention.

1.1 Cleaning of gold coated glass slide and MALDI probe.

A probe comprising a gold coated microscope glass slide or a MALDI probe was thoroughly cleaned before use with sequential washing steps in acetone, acetonitrile, double distilled water and dried under nitrogen.

1.2 Non protein binding layer incorporating protein binding moieties prepared and deposited

1.2.1 PEG-PLL derivative synthesis

PEG-PLL-Biotin:

100 mg poly-L-lysine average size 17-30 kda (Sigma, Dorset, UK) was reacted with 109 mg mPEG-SPA (Shearwater Corporation, Huntsville, Alabama) and 1.1 mg biotin PEG-CO-NHS in 100 mM carbonate buffer pH 9 for a period of 30 minutes. The reaction was terminated by dialysis in 1 mM Tris-HCl pH 7.5 over night. The product from this reaction was called 1% PEG-PLL-Biotin (1% PEG derivatives contain a biotin headgroup) and several other small ligand ratios were synthesized (1%, 2%, 10% and 20%).

PEG-PLL-Bleomycin:

10 mg of bleomycin B6 (Calbiochem,) was dissolved in 1 ml acetone and 7.5 mg EDC and NHS each was added. The pH of the reaction was adjusted with HCl at pH 3. In another reaction 99 mg poly-L-lysine was reacted with 11 mg DVS-PEG-CO-NHS and 100 mg mPEG-CO-NHS in 100 mM carbonate buffer pH 9. After 20 min both reactions were mixed and the pH was adjusted to pH 9 when necessary. The PEG-PLL-Bleomycin synthesis was cleaned up by a dialysis against a plentiful amount of 1 mM Tris-HCl pH 7.5 buffer over night. The product of this

synthesis was called 10% PEG-PLL-Bleomycin indicating that approximately 10% of the PEG side chains are substituted with Bleomycin.

Freshly prepared affinity capture polymer, for example, 1% PEG-PLL-Biotin or 10% PEG-PLL-Bleomycin B6 was deposited onto the probe. The surface was then covered with Nesco film to evenly distribute the protein capture moiety over the probe. After 30 min the probe was washed in 1 mM Tris-HCL pH 7.5 and dried under nitrogen.

The PEG-PLL-Bleomycin B6 surface was ready for use.

1.3 Alternative protein capture moiety added if required

The PLL-PEG-biotin has a neutravidin molecule bound to the biotin by adding 0.5 mg/ml neutravidin for one hour at RT in a humid chamber. The Probe was then rinsed with washing buffer, and washed twice with ample desalting buffer before it was dried under nitrogen. The surface was now ready to be used as a highly specific affinity capture of macromolecules carrying an appropriate affinity tag, e.g. Biotin or phleomycin/zeocin resistance binding protein.

2. Preparation of a protein microarray according to one aspect of the invention.

2.1 Tagged proteins produced

Purified mRNA from heart, liver or breast tissues are transcribed into cDNA using known techniques. The 3' end of the cDNA is made accessible to a 3' to 5' single-stranded exonuclease which digests one strand of the DNA. The reaction is controlled through manipulation of parameters such as time, temperature and salt concentration. The remaining single stranded region of DNA is then removed by a single-stranded nuclease such as mung bean nuclease, to leave a blunt end. The resulting truncated double stranded cDNA is then digested with a rare-cutting restriction enzyme which has a site at the 5' end of the cDNA, introduced during cDNA synthesis. The resulting cDNA fragment is then ligated to a DNA tag which encodes a marker of solubility. In this case, this is achieved by ligating the cDNA fragment into a vector

which provides a tag 3' to the cDNA fragment. Transcription initiates upstream of the cloned cDNA and proceeds through the cDNA and downstream tag. When ligated in-frame and in the absence of stop codons, the resulting translation product consists of a polypeptide sequence derived from the cloned cDNA, fused to a tag which reports solubility of the fusion protein. This technique is applicable to both single cDNA and collections.

The version of the vector described here contains a tag which encodes the zeocin binding protein (ZBP), fused to Biotin Carboxyl Carrier Protein (BCCP) and the myc tag. The Applicant has demonstrated that both biotinylation of BCCP and the ability of the ZBP to confer resistance to Zeocin, is dependant on the solubility of the fusion protein. In addition, immediately upstream of the cloned cDNA, a small tag such as FLAG is encoded. The resulting expressed fusion protein contains tags at the N- and C-termini for quality control purposes. When the resulting modified cDNA library is transformed into *E. coli* and selected either on Zeocin or an analogue or is probed for biotinylation of BCCP, positive clones expressing soluble fusion proteins are identified.

2.2 Proteins bound

In one experiment, human liver cDNA was subjected to this methodology and the resulting library expressed in *E. coli*. Approximately 5,000 clones expressing soluble fusion proteins were clonally isolated and individually subjected to fermentation. The cells were lysed and the resulting soluble, biotinylated proteins captured and purified on a streptavidin-coated surface in a single step. A protein microarray consisting of several thousand members was produced, reflecting the expressed complement of the liver at the time of harvest.

3. Analysis of a protein array according to one aspect of the invention.

3.1 Crystals of energy absorbing molecules prepared

Solutions of energy absorbing molecules for overlaying a protein microarray were prepared as set out below: i) to iii) and vii) are preparations according to one aspect of

the invention whereas iv) to vi) are comparative preparations prepared according to prior art methods:

- i) α -cyano-4-hydroxycinnamic acid (Sigma, Dorset, UK) was dissolved in acetone at saturating amounts and 300 nanoliter of the solution was used to overlay the analyte.
- ii) Sinapinic acid (Sigma, Dorset, UK) was dissolved in acetone at saturating amounts and 300 nanoliter of the solution was used to overlay the analyte.
- iii) Gentisic acid (Sigma, Dorset, UK) was dissolved in acetone at saturating amounts and 300 nanoliter of the solution was used to overlay the analyte.
- iv) 10 mg/ml α -cyano-4-hydroxycinnamic acid (Sigma, Dorset, UK) was dissolved in 50 % v/v acetonitrile, 0.1% trifluoroacetic acid as known in the art and 300 nanoliter of the solution is used to overlay the analyte on the probe.
- v) Sinapinic acid (Sigma, Dorset, UK) was dissolved in ddH₂O at saturating amounts and 300 nanoliter of the solution is used to overlay the analyte.
- vi) Gentisic acid (Sigma, Dorset, UK) was dissolved in ddH₂O at saturating amounts and 300 nanoliter of the solution was used to overlay the analyte.
- vii) α -cyano-4-hydroxy-cinnamic acid (Sigma, Dorset, UK) is dissolved in 99% acetone v/v, 1% glycerol in saturating amounts. 3 nanoliter of the matrix formulation is then transferred onto the probe, which contains the analyte.

3.2 Generic method for microcrystallisation of energy absorbing matrix molecules

The three examples of energy absorbing molecules prepared as described in 3.1 above were arrayed onto a protein microarray and the appearance at 100 fold magnification is illustrated in Fig 1a. The acetone dissolved matrix i) , ii) and iii) show a very

homogenous crystal formation compared with the aqueous matrix iv), v) and vi) formulation currently used in the art

Referring to Fig 1a the left hand side slides show the acetone dissolved formulations whereas on the right hand side the aqueous matrix formulation are shown.

The new matrix formulation illustrated have proved significant in being able to generate protein microarrays (see Figure 1b) because they allow a more efficient use of space on the probe surface, have enhanced flatness allowing greater mass accuracy, and furthermore increased amounts of matrix can be deposited on the probe to meet the needs of high analyte density.

Fig 1b illustrates a probe according to one aspect of the invention with protein captured thereon (thus forming a protein microarray) with an energy absorbing matrix according to a further aspect of the invention overlaid. The α -cyano-4-hydroxy-cinnamic acid matrix was dissolved in acetone 99% v/v, 1% glycerol v/v and arrayed onto a gold coated microscope slide. After solvent evaporation, matrix crystals are formed. In contrast to the crystals formed by the deposit of aqueous solutions the non-aqueous solvent formulation of matrix lead to a very homogeneous and flat crystal layer. Because of this the analyst looking at the spots can "hit" the analyte within the "spot" and consequently the spot can be made smaller enabling the miniaturization and production of a microarray because of the resulting high spatial density, which could not be created using aqueous matrix formulations. This is a significant development in the creation of mass spectrometric compatible protein microarrays.

4. Protein array subjected to MALDI and different methods of use.

4.1 Surface capture of substantially pure tagged biological macromolecules

Example 1

Affinity capture of a variety of tagged proteins can be demonstrated using for example PEG-PLL-biotin or PEG-PLL-Bleomycin B6 as the protein capturing moieties.

Figs 2, a and b show the mass spectra acquired from a protein microarray demonstrating respectively the capture of 1500 and 15 femtogram of biotin tagged insulin. The biotin tagged insulin was arrayed onto an affinity capture surface on a gold coated microscope glass slide in a 3 nanoliter volume using 300 micrometer pins (Q-Array, Genetix, New Milton, UK). The gold coated PEG-PLL-Biotin Neutravidin surface, was washed three times with 1 mM Tris-HCl pH 7.5, dried under a stream of nitrogen and overlaid with 3 nanolitre of α -cyano-4-hydroxy-cinnamic acid dissolved in 99% acetone v/v, 1% glycerol resulting in a spot with an radius of approximately 200 micrometer. The probe was analysed with a mass spectrometer MALDI TOF mass spectrometer. Several biotin tagged insulin peaks are visible due to the different degree of biotinylation. Two additional peaks are observed at 7300 dalton and 14600 dalton and these are Neutravidin $[MH]^+$ and $[MH]^{2+}$.

This example demonstrates the protein microarray capability of this system and shows the versatility of immobilising analytes on the probe surface for removal of salt that otherwise could interfere with the formation of gaseous ions as known in the art. Together with the new matrix formulation it demonstrates the capability of manufacturing protein microarrays for mass spectrometric analysis.

4.2 Surface capture and detection of recombinant protein on a probe surface from a crude extract

Example 2

A PLL-PEG-biotin neutravidin surface on a MALDI target is overlaid with 500 nanoliters of a biotinylated protein mixture derived from an *E. coli* lysate expressing a human recombinant protein in conjunction with a sequence tag in this case Biotin carboxyl carrier protein (BCCP) from *E. coli*. The protein was captured for a period of 2 hours on the surface, washed twice with washing buffer followed by two washes with desalting buffer, and overlaid with 300 nanoliters of an energy absorbing matrix, namely saturated α -cyano-4-hydroxycinnamic acid in acetone. The mass spectrum acquired in linear mode using the delayed extraction technique at low laser power is

illustrated in Fig 5. The advantage of this method is that the sample can be applied as a complex mixture of proteins and after washing only the molecules of interest remain. Secondly the analyte is captured in a spatially defined position before it is released from the affinity capture surface by the addition of matrix.

4.3 Capture, detection and identification of recombinant protein on probe using a degradation process

Example 3

Figure 6 shows the peptide fingerprint analysis of Glutathione-S-transferase -Biotin Carboxyl Carrier Protein (GST-BCCP). A bacterial crude lysate containing the fusion protein and bacterial proteins was placed on the MALDI target previously coated with PEG-PLL-biotin and neutravidin. The BCCP fusion partner of GST contained a biotinylation consensus sequence such that it becomes biotinylated when expressed in *E. coli*, allowing the fusion protein to bind specifically to the PEG-PLL-biotin neutravidin surface, whilst allowing the bacterial proteins to be washed away with buffer. For identification purpose the surface captured protein was digested by overlaying it with trypsin and analysed by MALDI MS. A protein fingerprint analysis revealed 12 peptides belonged to GST from *Schistosoma mansoni*, 4 peptides belonging to Neutravidin and 3 to trypsin (see table 1), but no bacterial protein was identified using the remaining un-matched peptides. This experiment demonstrates that PEG-PLL-biotin and neutravidin can be used to purify a protein from a crude mixture of protein in a single step on a MALDI target. Taken together this experiment paves the way for protein microarray production where the protein content on the array is derived from a bacterial expression system without the need for an initial pre-purification step.

Example 4

Figure 9a shows a mass spectrum of the biotinylated lectin from *Triticum vulgaris* (WGA) captured onto a PEG-PLL-Biotin Neutravidin surface. The lectin was then probed with the glycoprotein Fetuin and the MALDI target was washed and desalted. The mass spectrum reveals molecular ions of neutravidin at 14300 and 28600 dalton, the lectin was detected at 17700 and 35500 and Fetuin derived peaks were observed at 44163. Furthermore, there are two peaks present at 25943 and 32158 that had not been observed when the lectin was analysed in the absence of Fetuin and they might represent degradation products of the lectin since we observed several bands upon gel electrophoretic analysis of the Fetuin preparation. However the higher molecular weight band represented the main fraction of the protein. In Figure 9b the MALDI TOF spectrum of biotinylated *Arachis hypogea* lectin captured on a PEG-PLL-Biotin Neutravidin surface is shown. The lectin was probed with the same Fetuin solution as in Figure 9a. However the lectin from *Arachis hypogea* has a different binding affinity towards carbohydrates than the *Triticum vulgaris* lectin and it therefore enriched specifically the small fraction of glycoprotein that had no terminal sialic acid. The mass spectrum contains peaks derived from neutravidin at 14300 and peaks from the lectin at 25774 and 51461 dalton and two peaks derived from Asialofetuin are present at 40136 and 42731 consistent with the loss of 4 and 13 sialic acid groups. The last two experiments demonstrate the detection and analysis of protein-glycoprotein interactions on a protein array by mass spectrometry.

4.4 Detection of small molecules on protein microarrays

Example 5

To demonstrate the capability of small molecule detection in the presence of the PEG-PLL-biotin and Neutravidin three small molecules used in pharmacology and toxicology were spiked onto the array. The molecules Cyclosporin, Ketoconazole and Quinidine were identified at their corresponding molecular weight.

A PEG-PLL-biotin coated probe was incubated with a solution of Neutravidin and washed extensively with washing buffer (1 mM Tris-HCl pH 7.5 with 0.1% Triton X-100) and desalting buffer (1 mM Tris-HCl pH 7.5.), dried and overlaid with energy absorbing matrix and then analysed with MALDI TOF mass spectrometry.

The mass spectra (Figure 3a, 3b and 3c) show the specific capture of Neutravidin $[MH]^+$ and $[MH]^{2+}$ at 7310 and 14652 dalton.

Example 6

In a further example the binding of a small molecule to a protein is demonstrated in Figures 10a, b, and c. The lactose rhodamine conjugate was specifically retained on a PEG-PLL-Neutravidin Arachis hypogea lectin surface whereas it could not be detected on a PEG-PLL-Neutravidin FK506 binding protein surface. This is another example for the detection of a small molecule protein interaction. The example is surprising since binding constant for lactose and this lectin is in the millimolar range, suggesting that the presence of the rhodamine moiety has increased the affinity of the small molecule ligand.

4.5 Detection of a reactant on a protein microarray

Example 7

ATP was enzymatically synthesized from the reaction of ADP, creatine phosphate and creatine phosphate kinase in 25 mM ammonium bicarbonate at pH 7.4. $[ADP]^-$ was detected at 427.6 dalton and $[ADP+Na]^-$ 449.6 dalton (see Fig 4a). The products of the creatine phosphate kinase reaction were detected at 507.6, 529.6, 551.6 and 573.8,

which fits well with the expected molecular weight of $[ATP]^-$ and three ATP sodium adducts $[ATP Na]^-$, $[ATP Na_2]^-$ and $[ATP Na_3]^-$.

Control reactions in which either one of the substrates ADP or creatine phosphate or the enzyme creatine phosphate kinase were omitted didn't show ATP peaks.

4.6 Detection of a reactant on a protein microarray

Example 8

The oxidation of drug-like small molecules by human cytochrome P450 enzymes is the usual first step in the metabolism of such compounds.

Here, the oxidation of dibenzylfluorescein by cytochrome P450 3A4 was studied with MALDI MS and the results illustrated in Fig 4b. Dibenzylfluorescein (DBF) was detected at 513.795 $[MH]^+$ and a metastable oxidation product was observed at 530.069, which indicates the addition of one oxygen. The resulting molecule is known to be chemically unstable and therefore monobenzylfluorescein (MBF) and their oxidation products can be observed at 444.912 $[MH]^+$, 460.890 $[MH+O]^+$ and 476.855 $[MH+2O]$ dalton.

This experiments shows the suitability of a protein arrays to detect biological catalysis and to assign function to biological polypeptides captured on protein arrays.

The mass spectra from the figures listed below had been obtained on

1. Bruker Daltonic gold targets #26993 (Figure 3a, 3b, 3c, 4, 5)
2. Bruker Daltonic glass target #26754 (Figure 6)
3. Bruker Daltonic MTP 384 target milled out to harbor a gold coated microscope 30 x 75 mm glass slide (Figure 2a, 2b)

CLAIMS

1. A probe, for use with a laser desorption/ ionisation mass spectrometer, comprising a support having an electroconductive target surface thereon characterized in that the target surface comprises a micro array having a plurality of discrete target areas presenting one or more analyte capture moieties.
2. A probe as claimed in claim 1 wherein the support is a glass slide, or a MALDI target.
3. A probe as claimed in claim 1 or 2 wherein the plurality of discrete target areas are arranged in a spatially defined manner.
4. A probe as claimed in any of the preceding claims wherein each discrete target area has an area of less than $1000\mu\text{m}^2$, more preferably still less than $500\mu\text{m}^2$, and more preferably still less than $100\mu\text{m}^2$.
5. A probe as claimed in any of the preceding claims wherein each discrete target area has an area of less than $785\mu\text{m}^2$, more preferably less than $392\mu\text{m}^2$, more preferably still less than $78\mu\text{m}^2$.
6. A probe as claimed in any of the preceding claims wherein the discrete target areas are substantially circular.
7. A probe as claimed in any of the claims wherein the discrete target areas are arranged in matrices.
8. A probe as claimed in claim 7 wherein there are a plurality of matrices on the target surface.

9. A probe as claimed in claim 7 or 8 wherein the matrices comprise at least 2 rows and 2 columns of discrete target areas.
10. A probe as claimed in any of the preceding claims comprising at least 10, more preferably at least 100, more preferably still at least 1000, and more preferably still at least 10000 discrete target areas.
11. A probe as claimed in any of the preceding claims wherein there is a spacing between adjacent discrete target areas in a matrix of less than 1mm.
12. A probe as claimed in any of the preceding claims wherein the electroconductive surface comprises a metal or a semi conductor.
13. A probe as claimed in claim 12 wherein the metal is selected from gold, silver, platinum, iridium, iron, nickel, cobalt, copper or a mixture or alloy thereof and the semi conductor is selected from silicon, graphite or germanium.
14. A probe as claimed in any of the preceding claims wherein the analyte capture moieties are protein capture moieties.
15. A probe as claimed in claim 14 wherein the protein capture moiety is not an antibody.
16. A probe as claimed in claim any of claims 1 to 12 wherein the analyte capture moieties are small molecules.
17. A probe as claimed in claim 16 wherein the small molecules are less than 2 kDa, preferably less than 1 kDa, more preferably less than 500 Da.
18. A probe as claimed in any of the preceding claims wherein the analyte capture moieties are homogenously disposed in the discrete target areas.
19. A probe as claimed in any of the preceding claims wherein the analyte capture moieties are disposed in the discrete target areas in a defined orientation.

20. A probe as claimed in any of the preceding claims wherein the analyte capture moieties have a high affinity for their binding partner.
21. A probe as claimed in claim 20 wherein the binding affinity (K_d) between the analyte capture moiety and its binding partner is at least $10^{-7}M$, more preferably at least $10^{-9}M$, more preferably at least $10^{-12}M$, and more preferably still at least $10^{-15}M$.
22. A probe as claimed in any of the preceding claims wherein the analyte capture moiety is attached directly to the electroconductive target surface.
23. A probe as claimed in any of claims 1 to 21 wherein the analyte capture moiety is indirectly attached to the electroconductive target surface.
24. A probe as claimed in claim 23 wherein the analyte capture moiety is attached via one or more linker molecules.
25. A probe as claimed in claim 24 wherein the linker molecules comprises a poly amino acid or an alkane thiol.
26. A probe as claimed in claim 25 wherein poly amino acid is poly-L-lysine, poly-L-aspartic acid, poly-L-glutamic acid or mixtures of any other known aminoacids with the three aforementioned aminoacids. .
27. A probe as claimed in claim 14 wherein at least one protein capturing moiety binds biotin or a bleomycin resistance protein.
28. A probe as claimed in claim 27 wherein the protein capturing moiety is streptavidin, avidin, neutravidin or bleomycin.
29. A probe as claimed in any of the preceding claims wherein the analyte capture moiety is provided in a layer which is otherwise substantially resistant to non specific protein binding.

30. A probe as claimed in claim 29 wherein the layer which is otherwise substantially resistant to non specific protein binding comprises a polymer or a self assembled monolayer (SAM) which is responsible for the generally protein repellant nature of the layer.
31. A probe as claimed in claim 30 wherein the polymer comprises polyethylene glycol (PEG), dextran, polyurethane or polyacrylamide.
32. A probe as claimed in claim 31 wherein the polymer is bound to the probe surface via one or more linker molecules.
33. A probe as claimed in claim 32 wherein the analyte capturing moiety is attached to the surface via the polymer and / or the linker molecules.
34. A probe as claimed in any of the preceding claims wherein a single common analyte capture moiety is provided on the surface.
35. A probe as claimed in any of claims 1 to 33 wherein a plurality of different analyte capturing moieties are provided on the surface.
36. A probe as claimed in any of the preceding claims further comprising a captured analyte.
37. A probe as claimed in claim 36 wherein the captured analyte comprises a protein.
38. A probe as claimed in claim 37 wherein the protein is a fusion protein.
39. A probe as claimed in claim 38 wherein the fusion protein comprises a biotin carboxyl carrier protein (BCCP).
40. A probe as claimed in claim 38 wherein the fusion protein comprises a phleomycin/zeocin resistance protein

41. A probe as claimed in any of claims 36 to 40 wherein the captured analyte has a further molecule bound to it.
42. A probe as claimed in claim 41 wherein the further molecule is either a small molecule, a protein or a nucleic acid .
43. A probe as claimed in any of the preceding claims wherein the analyte capturing moieties are homogeneously disposed across substantially the whole of the surface.
44. A probe as claimed in any of claims 1 to 43 wherein the analyte capturing moieties are homogenously disposed in only the discrete target areas.
45. A probe as claimed in any of claims 36 to 44 wherein the analyte is printed onto the surface.
46. A probe as claimed in any of claim 45 wherein the analyte is printed using, inkjet printing, piezo electric printing or contact printing.
47. A probe as claimed in claim 46 wherein for the contact printing the analyte is applied using a split pin, solid pin or a hollow pin
48. A probe as claimed in any of the preceding claims wherein the surface in the discrete target areas is substantially planar.
49. A probe as claimed in claim 48 wherein the discrete target areas are flat bottomed wells.
50. A probe as claimed in any of the preceding claims which can bind an analyte at a concentration of below 10^{15} molecules per $1000\mu\text{m}^2$, more preferably at a concentration of below 10^{12} molecules per $1000\mu\text{m}^2$, more preferably at a concentration of below 10^9 molecules per $1000\mu\text{m}^2$, more preferably still at a concentration of below 10^6 molecules per $1000\mu\text{m}^2$.

51. A method of producing a protein microarray for use with laser desorption ionization mass spectrometer comprising providing a probe as claimed in claim 14 and depositing protein in registration with the protein capturing moieties in the discrete target area.
52. A method of analysing a protein microarray as claimed in claim 51 comprising subjecting the protein microarray to laser desorption/ ionisation mass spectrometry.
53. A method as claimed in claim 52 wherein the laser desorption/ ionisation mass spectrometry is matrix assisted laser desorption/ ionisation mass spectrometry MALDI.
54. A method as claimed in claim 53 wherein energy absorbing molecules are deposited over the whole surface or in registration with the discrete target area on which a protein has been captured.
55. A method as claimed in claim 54 wherein energy absorbing molecules are deposited in registration with the discrete target area on which a protein has been captured.
56. A method as claimed in claims 54 or 55 in which the energy absorbing molecules are deposited in a manner which denatures and thus unbinds the protein from the protein capturing moieties leaving the denatured protein in close proximity to the protein capture moiety on the surface.
57. A method as claimed in any of claims 54 or 55 wherein the energy absorbing molecules are present as a homogenous layer in the discrete target area in registration with the protein capturing moieties and captured protein.
58. A method as claimed in claim 57 wherein the homogenous layer is substantially continuous such that individual crystals are not visible at a 100 fold magnification and there are no visible gaps between neighboring crystals.

59. A method as claimed in claim 57 or 58 wherein the homogenous layer is of a substantially uniform depth such that there is no apparent variation in crystal size at 100 fold magnification.
60. A method as claimed in any of claims 54 to 59 wherein the energy absorbing molecules are deposited onto the surface in a non aqueous solvent and the non aqueous solvent is evaporated off.
61. A method as claimed in claim 60 wherein the non aqueous solvent is an organic solvent.
62. A method as claimed in claim 61 wherein the organic solvent is acetone or butanone.
63. A method as claimed in any of claims 54 to 62 wherein the non aqueous solvent includes a modifier which controls the rate of evaporation such that evaporation of the non aqueous solvent occurs after the energy absorbing molecules are deposited.
64. A method as claimed in claim 63 wherein the modifier which controls the rate of evaporation is glycerol, polyetheleglycol or thioglycerol.
65. A method as claimed in any of claims 54 to 64 wherein the energy absorbing molecules are deposited in a mixture of from 80 - 99.9%, preferably 99%, non aqueous solvent, preferably acetone, to 20 - 0.1% , preferably 1%, modifier, preferably glycerol (vol/vol) .
66. A method as claimed in any of claims 54-65 wherein the energy absorbing molecules comprises crystals of α -cyano-4-hydroxy-cinnamic acid, sinapinic acid, gentisic acid, nifidine, succinic acid, 1,8,9,-anthracenitriol, 3-Indoleacrylic acid, 2-(hydroxyphenylazo) benzoe-acid, 4-nitroanilin and combinations thereof.

67. A method of analysis by laser desorption/ionisation mass spectrometry comprising the steps of:

- a) providing a probe as claimed in claim 14;
- b) bringing said probe into contact with one or more proteins;
- c) performing laser desorption/ ionisation mass spectrometry on the proteins on the surface of the probe.

68. The method of claim 67 which comprises between step b) and c) an additional step of removing unbound molecules from the probe by washing.

69. The method of claim 68 wherein said one or more proteins are contained in a mixture of proteins.

70. The method of any of claims 67 to 69 which is a method for identifying a protein on the surface of the probe and which comprises the additional steps of:

- d) determining the mass of the protein molecule;
- e) performing a digestion upon a replicate sample of said protein on a further probe or probe surface; and
- f) performing laser desorption/ ionisation mass spectrometry on the peptides resulting from step e) to identify said proteins.

71. The method of any of claims 67 to 69 which is a method of analysing the function of a protein on the surface of the probe and a molecule interacting with said protein and which comprises the additional steps instead of step c) of:

- c) bringing a protein on the probe surface into contact with one or more test molecules;
- d) removing unbound test molecules from the probe surface;
- e) performing laser desorption/ ionisation mass spectrometry on the protein and any bound molecule to determine the identity of the protein and/or test molecule.

72. The method of claim 71 wherein the test molecule is a small molecule, protein or nucleic acid.

73. The method of any of claims 67 to 69 which is a method of analysing the function of a protein and which comprises the additional steps of:

- c) bringing a protein on the probe surface into contact with one or more test substrates
- d) performing laser desorption/ ionisation mass spectrometry on the protein and test substrates to determine the presence and/or identity of products of catalysis of said test substrates by the protein.

References Cited

Brockman AH, Orlando R. Probe-immobilized affinity chromatography/mass spectrometry. Anal Chem. 1995, 67(24), 4581-4585.

Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M, Hofert C, Schelder M, Brajenovic M, RuffnerH, Merino A, Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B, Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti-Furga G. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415(6868),141-147.

Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. Gelb, M. H. and Aebersold, R, Quantitative analysis of complex protein mixtures using isotope-coded affinity tags.Nat Biotechnol. 1999,17 ,994-999

Hutchens, T. W. and Yip, T. T. New desorption strategies for mass spectrometric analysis of macromolecules. Rapid Communication in mass spectrometry 1993, 576-580

Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988, 60(20):2299-301.

Kukar, T. Eckenrode, S., Gu, Y., Lian, W. Megginson, M. She, J. X., and Wu, D., Protein microarrays to detect protein-protein interactions using red and green fluorescent proteins. *Analytical Biochemistry* 2002, 306, 50-54.

MacBeath, G., and Schreiber, S. F., Printing proteins as microarrays for high-throughput function determination, *Science* 2000, 289, 1760-1763.

MacBeath, G., Proteomics comes to the surface. *Nature Biotechnology* 2001, 19, 826-827.

Ruiz-Taylor LA, Martin TL, Zaugg FG, Witte K, Indermuhle P, Nock S, Wagner P. Monolayers of derivatized poly(L-lysine)-grafted poly(ethylene glycol) on metal oxides as a class of biomolecular interfaces. *Proc Natl Acad Sci U S A*. 2001,98(3):852-857.

Schweitzer, B., Roberts, S., Grimwalde, B., Shao, W., Wang, M., Fu, Q., Shu, Q., Laroche, I., Zhou, Z., Tchernev, V. T., Christiansen, J. Velleca, M., and Kingsmore, S. F., Multiplexed protein profiling on microarrays by rolling-circle amplification. *Nature Biotechnology* 2002, 20 359-365.

Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. *Int J Cancer*. 2001, 92(6):871-876.

Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N, Jansen R, Bidlingmaier S, Houfek T, Mitchell T, Miller P, Dean RA, Gerstein M, Snyder M. Global analysis of protein activities using proteome chips. *Science*. 2001 293, 2101-2105.


Zhu, H., and Snyder, M., 'Omic' approaches for unravelling signalling networks. *Current Opinion in Cell Biology* 2002, 14, 173-179.

I

Experimental Section


Figure 1) Matrix formulation for protein microarray.

a)




2

b)




3

Figure 2) Insulin-biotin mass spectra acquired from a protein nano-array spotting down 1500 and 15 fg before washing.




4

Capture of 16 fg insulin-biotin on a protein microarray




5

Figure 3a) Cyclosporin detection in the presence of PEG-PLL-Biotin and neutravidin.




6

Figure 3b) Ketoconazole detection in the presence of PEG-PLL-Biotin and neutravidin.



7

Figure 3c) Quinidine detection in the presence of PEG-PLL-Biotin and neutravidin.



8

Figure 4a) Detection of ADP and ATP with MALDI-TOF MS






Figure 4b) Detection of human cytochrome P450 oxidation products



10

Figure 5) Capture of 72 Kda biotinylated protein from a COVET experiment using a cardiac library



5

10

Figure 6) Glutathione-S-Transferase-Biotin captured on Neutravidin coated MALDI glass target.




Figure 7) Coupling procedures for proteins on surfaces.

Random coupling

Ordered coupling

BCCP-fusion-
biotin

Neutravidin

PEG-PLL-biotin


Amine coupling

PEG-PLL

12

Figure 8) Analysing PEG-PLL-Biotin affinity capture surface with a dual wavelength interferometer.

5



13

Figure 9a





Figure 9b



14

Figure 10a Mass spectrum of captured Lactose Rhodamine on PEG-PLL-biotin Neutravidin surface coated with Peanut lectin.






Figure 10 b Mass spectrum of Lactose Rhodamine prior capture on Peanut lectin



15

Figure 10c) Mass spectrum of FK506 binding protein that was immobilised onto a PEG-PLL-biotin neutravidin surface and probed with Lactose Rhodamin



5

Table 1

Peptide masses [M-H] ⁺	Glutathione-S- transferase	Trypsin	Avidin
770.416	X		
919.52	X		
963.497	X		
1026.563	X		
1032.574	X		
1094.56	X		
1138.518	X		
1149.628	X		
1182.645	X		
1314.736	X		
1516.828	X		
2326.1	X		
845.5		X	
2211.1		X	
2283.094		X	
919.53			X
1235.48			X
1595.845			X
2003.022			X